- American City Business Journals•last month
The new microbiome research site in Cambridge planned by Merck & Co. will be at the 50,000-square-foot former facility of Idenix Pharmaceuticals, which the New Jersey-based drug giant acquired in 2014. A company spokeswoman did not say how many employees would be at the new early discovery research facility. The spokeswoman said the facilty, first reported late Tuesday , it will open in “late 2016.” The person who will oversee it — Daria Hazuda, Merck’s head of Infectious Diseases and Vaccines discovery research — will split her time between Cambridge and Merck’s facility in West Point, Pa.
- Motley Fool•last year
Big Pharma Merck is scheduled to report its second-quarter earnings results on July 28. Here are three questions investors are expecting to have answered on that date.
- CNBC•2 years ago
Activist hedge fund Sarissa Capital will nominate two directors to Ariad Pharmaceuticals' board and seek the "imminent retirement" of Chief Executive Harvey Berger.
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|